炎症性肠病
肠道通透性
医学
疾病
JAK-STAT信号通路
斯达
炎症
免疫系统
免疫学
克罗恩病
信号转导
癌症研究
生物信息学
生物
内科学
受体
车站3
细胞生物学
酪氨酸激酶
作者
Hillmin Lei,Meli’sa Crawford,Declan F. McCole
出处
期刊:Pharmaceuticals
[Multidisciplinary Digital Publishing Institute]
日期:2021-08-25
卷期号:14 (9): 840-840
被引量:18
摘要
The epithelial barrier forms the interface between luminal microbes and the host immune system and is the first site of exposure to many of the environmental factors that trigger disease activity in chronic inflammatory bowel disease (IBD). Disruption of the epithelial barrier, in the form of increased intestinal permeability, is a feature of IBD and other inflammatory diseases, including celiac disease and type 1 diabetes. Variants in genes that regulate or belong to the JAK-STAT signaling pathway are associated with IBD risk. Inhibitors of the JAK-STAT pathway are now effective therapeutic options in IBD. This review will discuss emerging evidence that JAK inhibitors can be used to improve defects in intestinal permeability and how this plays a key role in resolving intestinal inflammation.
科研通智能强力驱动
Strongly Powered by AbleSci AI